{"nctId":"NCT01626885","briefTitle":"A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia","startDateStruct":{"date":"2012-05"},"conditions":["Schizophrenia"],"count":42,"armGroups":[{"label":"MP-214 1.5-9 mg","type":"EXPERIMENTAL","interventionNames":["Drug: MP-214"]}],"interventions":[{"name":"MP-214","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent obtained from the patient before the initiation of any study-specific procedures\n* Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia\n* Patients who receive 1 or more antipsychotic drugs\n* Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)\n\nExclusion Criteria:\n\n* Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder\n\nThe information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":42},"commonTop":["Nasopharyngitis","Schizophrenia","Headache","Somnolence","Blood creatine phosphokinase increased"]}}}